IP Library › Granted Patent US 12,428,473
Granted Patent B2
US 12,428,473 · App. 17/454,837 · Granted Sep 30, 2025

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

Inventors: Antonio Digiandomenico (Gaithersburg, MD); Paul Warrener (Gaithersburg, MD); Charles Stover (Gaithersburg, MD); Bret Sellman (Gaithersburg, MD); Ralph Minter (Cambridge, GB); Sandrine Guillard (Cambridge, GB); Steven Rust (Cambridge, GB); Mladen Tomich (Exton, PA); Vignesh Venkatraman (Cambridge, GB); Reena Varkey (Gaithersburg, MD); Li Peng (Gaithersburg, MD); Melissa Damschroder (Gaithersburg, MD); Partha S. Chowdhury (Gaithersburg, MD); Nazzareno Dimasi (Gaithersburg, MD); Ryan Fleming (Gaithersburg, MD); Binyam Bezabeh (Gaithersburg, MD); Changshou Gao (Gaithersburg, MD); Godfrey Rainey (Gaithersburg, MD); Cuihua Gao (Gaithersburg, MD)
Assignee: MedImmune Limited
C07K16/1214A61K2039/505A61K2039/507A61P31/04C07K2317/21C07K2317/31C07K2317/33C07K2317/56C07K2317/565C07K2317/622C07K2317/734C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,473
App. No.
17/454,837
Granted
Sep 30, 2025
Kind
B2
Abstract

This disclosure relates to combination therapies comprising anti- Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.

Claims (24)

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to Pseudomonas PcrV, wherein the antibody or antigen-binding fragment thereof comprises:

(a) the heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:218; the heavy chain CDR2 comprising amino acids 50-66 of SEQ ID NO:264; and the heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:220; and

(b) the light chain CDR1 comprising the amino acid sequence of SEQ ID NO:221; the light chain CDR2 comprising the amino acid sequence of SEQ ID NO:222; and the light chain CDR3 comprising the amino acid sequence of SEQ ID NO:223.

2. The antibody or antigen-binding fragment thereof of claim 1 , comprising:

(a) the heavy chain variable region comprising amino acids 1-124 of SEQ ID NO:264; and

(b) the light chain variable region comprising amino acids 1-107 of SEQ ID NO:263.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a recombinant monoclonal antibody or antigen-binding fragment thereof.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a bispecific antibody or antigen-binding fragment thereof.

5. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is a recombinant monoclonal antibody or antigen-binding fragment thereof.

6. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is a bispecific antibody or antigen-binding fragment thereof.

7. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a full-length antibody.

8. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment.

9. The antibody or antigen-binding fragment thereof of claim 8 , wherein the antigen-binding fragment is selected from the group consisting of: Fab fragment, Fab′ fragment, F(ab)2 fragment, and scFv fragment.

10. The antibody or antigen-binding fragment thereof of claim 4 , wherein the antibody or antigen-binding fragment thereof is an IgG antibody.

11. The antibody or antigen-binding fragment thereof of claim 10 , wherein the antibody or antigen-binding fragment thereof is an IgG1 antibody.

12. The antibody or antigen-binding fragment thereof of claim 6 , wherein the antibody or antigen-binding fragment thereof is an IgG antibody.

13. The antibody or antigen-binding fragment thereof of claim 12 , wherein the antibody or antigen-binding fragment thereof is an IgG1 antibody.

14. The antibody or antigen-binding fragment thereof of claim 4 , wherein the antibody or antigen-binding fragment thereof comprises a IgGκ constant region.

15. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a IgGλ constant region.

16. The antibody or antigen-binding fragment thereof of claim 6 , wherein the antibody or antigen-binding fragment thereof comprises a IgGκ constant region.

17. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof comprises a IgGλ constant region.

18. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.

19. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 2 , and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2021
From: MINTER, RALPH; GUILLARD, SANDRINE; RUST, STEVEN; VENKATRAMAN, VIGNESH
To: MEDIMMUNE LIMITED
Reel/Frame 058333/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2021
From: MEDIMMUNE, LLC
To: MEDIMMUNE LIMITED
Reel/Frame 058334/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2021
From: DIGIANDOMENICO, ANTONIO; WARRENER, PAUL; STOVER, CHARLES; SELLMAN, BRET; VARKEY, REENA; PENG, LI; DAMSCHRODER, MELISSA; CHOWDHURY, PARTHA S.; DIMASI, NAZZARENO; FLEMING, RYAN L.; BEZABEH, BINYAM; GAO, CHANGSHOU; RAINEY, GODFREY J.; TOMICH, MLADEN; GAO, CUIHUA
To: MEDIMMUNE, LLC
Reel/Frame 058387/0788 →
Continuity (6)
Division 16789790 · Feb 13, 2020
Division 14356500
Provisional Application 61556645 · Nov 7, 2011
Provisional Application 61625299 · Apr 17, 2012
Provisional Application 61697585 · Sep 6, 2012
Related Publication 20220177554A1 · Jun 9, 2022
References Cited (192)
US 4444887A · Hoffmann · 1984 [cited by applicant]
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4716111A · Osband et al. · 1987 [cited by applicant]
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5089262A · Sawada et al. · 1992 [cited by applicant]
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5258498A · Huston et al. · 1993 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5516637A · Huang et al. · 1996 [cited by applicant]
US 5525491A · Huston et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5658570A · Newman et al. · 1997 [cited by applicant]
US 5658727A · Barbas et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5698426A · Huse · 1997 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5750753A · Kimae et al. · 1998 [cited by applicant]
US 5780225A · Wigler et al. · 1998 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 5821047A · Garrard et al. · 1998 [cited by applicant]
US 5892019A · Schlom et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5969108A · McCafferty et al. · 1999 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6190370B1 · Tsui · 2001 [cited by applicant]
US 6420140B1 · Hori et al. · 2002 [cited by applicant]
US 6458592B1 · Jakobovits et al. · 2002 [cited by applicant]
US 6827935B2 · Frank et al. · 2004 [cited by applicant]
US 7083784B2 · Dall'Acqua et al. · 2006 [cited by applicant]
US 7112324B1 · Dorken et al. · 2006 [cited by applicant]
US 7494653B2 · Frank et al. · 2009 [cited by applicant]
US 7658921B2 · Dall'Acqua et al. · 2010 [cited by applicant]
US 8501179B2 · Numata et al. · 2013 [cited by applicant]
US 8642039B2 · Yarranton · 2014 [cited by applicant]
US 9403901B2 · Digiandomenico et al. · 2016 [cited by applicant]
US 9527905B2 · Sellman et al. · 2016 [cited by applicant]
US 9580509B2 · Dimasi et al. · 2017 [cited by applicant]
US 9845348B2 · Sellman et al. · 2017 [cited by applicant]
US 9879070B2 · Sellman et al. · 2018 [cited by applicant]
US 10023654B2 · Sleeman et al. · 2018 [cited by applicant]
US 10072098B2 · De Tavernier et al. · 2018 [cited by applicant]
US 10370436B2 · Digiandomenico et al. · 2019 [cited by applicant]
US 10597439B2 · Digiandomenico · 2020 [cited by examiner]
US 10759849B2 · Sellman et al. · 2020 [cited by applicant]
US 10844114B2 · DiGiandomenico et al. · 2020 [cited by applicant]
US 10870710B2 · DiGandomenico et al. · 2020 [cited by applicant]
US 11066461B2 · Jafri et al. · 2021 [cited by applicant]
US 11203633B2 · Digiandomenico · 2021 [cited by examiner]
US 20020123057A1 · Zauderer et al. · 2002 [cited by applicant]
US 20020146753A1 · Ditzel et al. · 2002 [cited by applicant]
US 20030232387A1 · Lu · 2003 [cited by applicant]
US 20080095775A1 · Lewis et al. · 2008 [cited by applicant]
US 20080131423A1 · Mori et al. · 2008 [cited by applicant]
US 20090191186A1 · Bebbington et al. · 2009 [cited by applicant]
US 20090215992A1 · Wu et al. · 2009 [cited by applicant]
US 20100150939A1 · Blanchetot et al. · 2010 [cited by applicant]
US 20100166768A1 · Sleeman et al. · 2010 [cited by applicant]
US 20100172862A1 · Correia et al. · 2010 [cited by applicant]
US 20100272736A1 · Baer et al. · 2010 [cited by applicant]
US 20110150896A1 · Numata et al. · 2011 [cited by applicant]
US 20140227285A1 · Digiandomenico et al. · 2014 [cited by applicant]
US 20140302038A1 · Dimasi et al. · 2014 [cited by applicant]
US 20150023966A1 · Digiandomenico et al. · 2015 [cited by applicant]
US 20150044215A1 · De Tavernier et al. · 2015 [cited by applicant]
US 20150239660A1 · Egersdoerfer et al. · 2015 [cited by applicant]
US 20150284450A1 · Digiandomenico et al. · 2015 [cited by applicant]
US 20160115250A1 · Digiandomenico et al. · 2016 [cited by applicant]
US 20160297872A1 · Digiandomenico et al. · 2016 [cited by applicant]
US 20170114151A1 · Dimasi et al. · 2017 [cited by applicant]
US 20170129943A1 · Sellman et al. · 2017 [cited by applicant]
US 20170183397A1 · Digiandomenico et al. · 2017 [cited by applicant]
US 20180355026A1 · Jafri et al. · 2018 [cited by applicant]
US 20190055322A1 · De Tavernier et al. · 2019 [cited by applicant]
US 20190153076A1 · Weiner · 2019 [cited by examiner]
US 20190309095A1 · Jafri et al. · 2019 [cited by applicant]
US 20190322726A1 · Digiandomenico et al. · 2019 [cited by applicant]
US 20200317757A1 · Digiandomenico et al. · 2020 [cited by applicant]
US 20200392210A1 · Kyratsous et al. · 2020 [cited by applicant]
US 20210130442A1 · Digiandomenico et al. · 2021 [cited by applicant]
JP 2007533295A · 2007 [cited by applicant]
WO WO02096948A2 · 2002 [cited by applicant]
WO WO2006009525A2 · 2006 [cited by applicant]
WO WO2007024715A2 · 2007 [cited by applicant]
WO WO2008024188A2 · 2008 [cited by applicant]
WO WO2009092011A1 · 2009 [cited by applicant]
WO WO2010107778A1 · 2010 [cited by applicant]
WO WO2010108153A2 · 2010 [cited by applicant]
WO WO2010115606A1 · 2010 [cited by applicant]
WO WO2011005481A1 · 2011 [cited by applicant]
WO WO2012145626A1 · 2012 [cited by applicant]
WO WO2012170807A2 · 2012 [cited by applicant]
WO WO2013070565A1 · 2013 [cited by applicant]
WO WO2013070615A1 · 2013 [cited by applicant]
WO WO2014074470A1 · 2014 [cited by applicant]
WO WO2014074528A2 · 2014 [cited by applicant]
WO WO2014186358 · 2014 [cited by applicant]
WO WO2014186358A2 · 2014 [cited by applicant]
WO WO2015171504A1 · 2015 [cited by applicant]
WO WO2017193101A1 · 2017 [cited by applicant]
Lynch et al. Polymorphisms in the Pseudomonas aeruginosa Type III secretion protein, PcrV—implications for anti-PcrV Immunotherapy. Microb Pathog. Jun. 2010 ; 48(6): 197-204. (Year: 2010). [cited by examiner]
Bendig, Mary M. “Humanization of rodent monoclonal antibodies by CDR grafting,” Methods-Companion to Methods in Enzymology 8.2 (1995): 83-93. [cited by applicant]
Casset, F. et al. “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochemical and biophysical research communications 307(1): 198-205, Elsevier, Netherlands, (2003). [cited by applicant]
Colman, P. M. “Effects of amino acid sequence changes on antibody-antigen interactions.” Research in Immunology 145(1): 33-36, Elsevier, Netherlands (1994). [cited by applicant]
“Pseudomonas aeruginosa in Healthcare Settings,” CDC, Https://www.cdc.gov/hai/organisms/pseudomonas.html, accessed on Apr. 16, 2018, 2 pages. [cited by applicant]
Dimasi, N. et al., “The design and characterization of oligospecific anitbodies for simultaneous targeting of multiple disease mediators,” J. Mol. Biol. 393(3):672-92 (2009). [cited by applicant]
Galanos et al., “Galactosamine-induced sensitization to the lethal effects of endotoxin,” Proc Natl Acad Sci USA, vol. 76, No. 11, pp. 5939-5943 (1979). [cited by applicant]
Greenbaum, J. A. et al. “Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools,” Journal of Molecular Recognition: An Interdisciplinary Journal 20(2): 75-82, (2007). [cited by applicant]
Greenspan, N. S. et al. “Defining epitopes: It's not as easy as it seems.” Nature biotechnology 17(10): 936-937, (1999). [cited by applicant]
Harlow et al., In Antibodies a Laboratory Manual, Cold Spring Harbor Press, 1988, Chapter 3, pp. 23-35. [cited by applicant]
Höppner, Wolfgang, “Clinical Impact of Molecular Diagnostics in Endocrinology,” Hormone Research in Paediatrics 58, Suppl. 3: 7-15, (2002). [cited by applicant]
Ladner, “Mapping the epitopes of antibodies,” Biotechnol. Genet. Eng. Rev., 24:1-30 (2007). [cited by applicant]
Lodish et al., Mol. Cell Biol., 3rd ed. Scientific American Books, NY, 1995 (Year: 1995). [cited by applicant]
MacCallum, R. M. et al., “Antibody-antigen interactions: contact analysis and binding site topography,” Journal of molecular biology 262(5): 732-745, Elsevier, Netherlands (1996). [cited by applicant]
Paul, W.E., “Structure and Function of Immunoglobulins,” in Fundamental Immunology, Third Edition: pp. 292-295, Raven Press, New York, United States (1993). [cited by applicant]
Rudikoff, S. et al. “Single amino acid substitution altering antigen-binding specificity.” Proceedings of the National Academy of Sciences 79(6): 1979-1983, (1982). [cited by applicant]
Russian Patent Application No. 2018102606/10, Office Action (English Translation), dated May 20, 2019. [cited by applicant]
Thaden, J. T. et al. “Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide.” The Journal of infectious diseases 213(4): 640… [cited by applicant]
Borlee, B.R., et al., “Pseduonomonas aerugioonsa uses a cyclic-di-GMP-regulated adhesion to reinforce the biofilm extracellular matrix,” Molecular Microbiology 75(4):827-842, Blackwell Scientific Publications, England (… [cited by applicant]
Byrd, M.S., et al., “The Pseudomonas aeruginosa Exopolysaccharide PSL facilitates surface adherence and NF-kB activation in A549 cells,” MBIO 1(3):e00140-10, pp. 1-4 (2010). [cited by applicant]
Ma, L., et al., “Assembly and Development of the Pseudomonas aeruginosa Biofilm Matrix,” PLOS Pathogens 5(3): e31000354, pp. 1-11, PLOS, United States (2009). [cited by applicant]
Li, H., et al., “Epitope Mapping of Monoclonal Antibodies using Synthetic Oligosacchardies Uncovers Novel Aspects of Immune Recognition of the PSL Exopolysaccharide of Pseudomonas aeruginosa,” Chemistry a European Journ… [cited by applicant]
Digiandomenico, A., et al., “Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide PSL by phenotypic screening,” Journal of Experimental Medicine 209(7): 1273-1287, Rockefelle… [cited by applicant]
European Search Report and Search Opinion for EP Application No. EP 17 20 5254, Munich, Germany, mailed on Jul. 6, 2018, 7 pages. [cited by applicant]
Kobayashi, Y., “A human monoclonal antibody against [cited by applicant]
Pakula, et al., “Genetic analysis of protein stability and function,” [cited by applicant]
Franklin, M.J., et al., “Biosynthesis of the [cited by applicant]
Ali, S.O., et al., “Phase 1 Study of MEDI3902, an Investigational Anti-pseudomonas Aeruginosa Pcrv and Psl Bispecific Human Monoclonal Antibody in Healthy Adults,” Clinical Microbiology and Infection 25(5):629. e1-629,e… [cited by applicant]
Byrd M.S., et al., “Genetic and Biochemical Analyses of the Pseudomonas Aeruginosa Psl Exopolysaccharide Reveal Overlapping Roles for Polysaccharide Synthesis Enzymes in Psi and LPS Production,” Molecular Microbiology 7… [cited by applicant]
Casadevall, A and Scharff, M.D., “Serum Therapy Revisited: Animal Models of Infection and Development of Passive Antibody Therapy,” Antimicrobial Agents and Chemotherapy 38(8): 1695-1702 (Aug. 1994). [cited by applicant]
Casadevall, A and Scharff, M.D., “Return to the Past: the Case for Antibody-based Therapies in Infectious Diseases,” Clinical Infectious Diseases 21(1):150-161, Clinical Infectious Diseases, United States (Jul. 1995). [cited by applicant]
Chang, T. T., et al., “Synergistic Effect of 4-Hydroperoxycyclophosphamide and Etoposide on a Human Promyelocytic Leukemia Cell Line (HL-60) Demonstrated by Computer Analysis,” Cancer Research 45(6):2434-2439, American … [cited by applicant]
Choi, K. H., et al., “A TN7-based Broad-range Bacterial Cloning and Expression System,” Nature Methods 2(6):443-448, Nature Publishing Group, United States (Jun. 2005). [cited by applicant]
Craven, D. E, and Steger, K.A., “Nosocomial Pneumonia in Mechanically Ventilated Adult Patients: Epidemiology and Prevention in 1996,” Seminars in Respiratory Infections 11(1):32-53, W.B. Saunders, United States (Mar. 1… [cited by applicant]
Dall'Acqua, W.F., et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal of Biological Chemistry 281(33):23514-23524, American Society for Biochemistry and Mo… [cited by applicant]
Digiandomenico, A., et al., “A Multifunctional Bispecific Antibody Protects Against Pseudomonas Aeruginosa,” Science Translational Medicine 6(262):262ra155, pp. 1-13, American Association for the Advancement of Science,… [cited by applicant]
Digiandomenico, A., et al., “Intranasal Immunization With Heterologously Expressed Polysaccharide Protects Against Multiple Pseudomonas Aeruginosa Infections,” Proceedings of the National Academy of Sciences of the Unit… [cited by applicant]
Digiandomenico, A., et al., “Oral Vaccination of BALB/c Mice with [cited by applicant]
Dixon, R. A and Chopra I., “Polymyxin B and Polymyxin B Nonapeptide Alter Cytoplasmic Membrane Permeability in [cited by applicant]
Drabick, J. J., et al., “Covalent Polymyxin B Conjugate with Human Immunoglobulin G as an Antiendotoxin Reagent,” Antimicrobial Agents and Chemotherapy 42(3):583-588, American Society for Microbiology, United States (Ma… [cited by applicant]
Drenkard, E., “Antimicrobial Resistance of Pseudomonas Aeruginosa Biofilms,” Microbes and Infection 5(13):1213-1219, Elsevier, France (Nov. 2003). [cited by applicant]
Extended European Search Report for Application No. EP12796646.3, mailed on Feb. 2, 2015. [cited by applicant]
Francois, B., et al., “Safety and Pharmacokinetics of an Anti-PcrV Pegylated Monoclonal Antibody Fragment in Mechanically Ventilated Patients Colonized With Pseudomonas Aeruginosa: a Randomized, Double-Blind, Placebo-co… [cited by applicant]
Frank, D.W., et al., “Generation and Characterization of a Protective Monoclonal Antibody to Pseudomonas Aeruginosa PcrV,” The Journal of Infectious Diseases 186(1):64-73, Oxford University Press, United States (Jul. 20… [cited by applicant]
Guidet B., et al., “Endotoxemia and Bacteremia in Patients With Sepsis Syndrome in the Intensive Care Unit,” Chest 106(4):1194-1201, Elsevier, United States (Oct. 1994). [cited by applicant]
Hancock, R.E, and Speert, D.P., “Antibiotic Resistance in Pseudomonas Aeruginosa: Mechanisms and Impact on Treatment,” Drug Resist Updates 3(4):247-255, Churchill Livingstone, Scotland (Aug. 2000). [cited by applicant]
Herbert, W., et al., “Multifunctional Monoclonal Antibody Targeting Pseudomonas aeruginosa Keratitis in Mice,” Vaccines 8(4):638, 12 pages, Basel, Switzerland (Nov. 2020). [cited by applicant]
Hoang, T. T., et al., “A Broad-host-range Flp-FRT Recombination System for Site-specific Excision of Chromosomally-located DNA Sequences: Application for Isolation of Unmarked Pseudomonas Aeruginosa Mutants,” Gene 212(1… [cited by applicant]
Hoppner, W., “Clinical Impact of Molecular Diagnostics in Endocrinology,” Hormone Research 58 (Suppl 3):7-15, Basel, Switzerland (2002). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2012/063639, issued May 13, 2014,5 pages. [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2012/063722, issued May 13, 2014, 7 pages. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2012/063639, mailed Jan. 22, 2013, 5 pages. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2012/063722, mailed Mar. 25, 2013, 11 pages. [cited by applicant]
Jackson K.D., et al., “Identification of Psl, a Locus Encoding a Potential Exopolysaccharide That is Essential for Pseudomonas Aeruginosa Pao1 Biofilm Formation,” Journal of Bacteriology 186(14):4466-4475, American Soci… [cited by applicant]
Keller et al., American Journal of Respiratory and Critical Care Medicine, 2017, 195: abstract #A3918. abstract only (Year:2017). [cited by applicant]
Lyczak, J. B., et al., “Establishment of Pseudomonas Aeruginosa Infection: Lessons From a Versatile Opportunist,” Microbes and Infection 2(9):1051-1060, Elsevier, France (Jul. 2000). [cited by applicant]
Ma, L., et al., “Pseudomonas Aeruginosa Psl Is a Galactose- and Mannose-Rich Exopolysaccharide, ” Journal of Bacteriology 189(22):8353-8356, American Society for Microbiology, United States (Nov. 2007). [cited by applicant]
Mabry, R and Snavely, M., “Therapeutic Bispecific Antibodies: the Selection of Stable Single-chain Fragments to Overcome Engineering Obstacles,” Idrugs : the Investigational Drugs Journal 13(8):543-549, Thomson Reuters … [cited by applicant]
International Preliminary Report on Patentability in International Patent Application No. PCT/US2012/041538, issued Dec. 10, 2013, 8 pages. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2012/041538, mailed Jan. 25, 2013, 11 pages. [cited by applicant]
Moriyama, K., et al., “Protective Effects of Affinity-purified Antibody and Truncated Vaccines Against Pseudomonas Aeruginosa V-antigen in Neutropenic Mice,” Microbiology and Immunology 53(11):587-594, Wiley-Blackwell, … [cited by applicant]
Pier, G.B., “Pseudomonas Aeruginosa: A Key Problem in Cystic Fibrosis,” ASM News 64(6):339-347 (1998). [cited by applicant]
Preston, M. J., et al., “Rapid and Sensitive Method for Evaluating Pseudomonas Aeruginosa Virulence Factors During Corneal Infections in Mice,” Infection and Immunity 63(9):3497-3501, American Society for Microbiology, … [cited by applicant]
Ray, V., et al., “Anti-Psl Targeting of Pseudomonas Aeruginosa Biofilms for Neutrophil-mediated Disruption,” Scientific Reports 7(1): 16065, 12 pages, published online (Nov. 2017). [cited by applicant]
Sawa, T., et al., “Active and Passive Immunization With the Pseudomonas V Antigen Protects Against Type III Intoxication and Lung Injury,” Nature Medicine 5(4):392-398, Nature Publishing Company, United States (Apr. 199… [cited by applicant]
Schweizer, H. P., “Allelic Exchange in Pseudomonas Aeruginosa Using Novel ColE1-type Vectors and a Family of Cassettes Containing a Portable oriT and the Counter-selectable Bacillus Subtilis Sacb Marker,” Molecular Micr… [cited by applicant]
Tabor, D.E., et al., “Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates,” Journal of Infectious Diseases 218(12):1983-1994, … [cited by applicant]
Warrener, P., et al., “A Novel Anti-PcrV Antibody Providing Enhanced Protection Against Pseudomonas Aeruginosa in Multiple Animal Infection Models,” Antimicrobial Agents and Chemotherapy 58(8):4384-4391, American Societ… [cited by applicant]
Bailat S., et al., “Similarities and Disparities Between Core-specific and O-side-chain-specific Antilipopolysaccharide Monoclonal Antibodies in Models of Endotoxemia and Bacteremia in Mice,” Infection and Immunity 65(2… [cited by applicant]
Birkenmeier, G., et al., “Polymyxin B-Conjugated a2-Macroglobulin as an Adjunctive Therapy to Sepsis: Modes of Action and Impact on Lethality,” The Journal of Pharmacology and Experimental Therapeutics 318(2): 762-771 ,… [cited by applicant]
Bucklin, S. E and Morrison D.C., “Differences in Therapeutic Efficacy Among Cell Wall-active Antibiotics in a Mouse Model of Gram-negative Sepsis,” The Journal of Infectious Diseases 172(6): 1519-1527, University of Chi… [cited by applicant]
Digiandomenico, A., et al., “Controlling Pseudomonas Aeruginosa Infections Using a Novel Multifunction Antibody Design,” American Journal of Respiratory and Critical Care Medicine 189:A5239, Abstract (2014). [cited by applicant]
Dunn, D. L., et al., “Anticore Endotoxin F(Ab′)2 Equine Immunoglobulin Fragments Protect Against Lethal Effects of Gram-negative Bacterial Sepsis,” Surgery 96(2):440-446, Mosby, United States (Aug. 1984). [cited by applicant]
Liu, P. V. and Wang, S., “Three New Major Somatic Antigens of Pseudomonas Aeruginosa,” Journal of Clinical Microbiology 28(5):922-925, American Society for Microbiology, United States (May 1990). [cited by applicant]
Mikkelsen, H., et al., “Key Two-component Regulatory Systems That Control Biofilm Formation in Pseudomonas Aeruginosa,” Environmental Microbiology 13(7):1666-1681, Blackwell Science, England (Jul. 2011). [cited by applicant]
Miyazaki, S., et al., “Role of Exotoxin A in Inducing Severe Pseudomonas Aeruginosa Infections in Mice,” Journal of Medical Microbiology 43(3): 169-175, Microbiology Society, England (Sep. 1995). [cited by applicant]
Morrison, D. C. and Jacobs, D. M., “Binding of Polymyxin B to the Lipid A Portion of Bacterial Lipopolysaccharides,” Immunochemistry 13(10):813-818, Pergamon Press, England (Oct. 1976). [cited by applicant]
Secher, T., et al., “Anti-pseudomonas Aeruginosa Serotype O11 LPS Immunoglobulin M Monoclonal Antibody Panobacumab (KBPA101) Confers Protection in a Murine Model of Acute Lung Infection,” The Journal of Antimicrobial Ch… [cited by applicant]
Supplementary European Search Report Corresponding to EP12847479 dated Feb. 2, 2016, 18 pages. [cited by applicant]
Liu, P.V., et al., “Survey of Heat-Stable, Major Somatic Antigens of Pseudomonas aeruginosa,” Int. J. of Syst. and Evol. Microbiology, vol. 33, No. 2, pp. 256-264 (Apr. 1983). [cited by applicant]
Cao, Y., et al., “Bispecific Antibodies as Novel Bioconjugates,” Bioconjugate Chemistry, 9(6): 635-644, American Chemistry Society, United States (1998). [cited by applicant]
Office action mailed Mar. 4, 2021, in U.S. Appl. No. 16/789,790, inventor Digiandomenico; Antonio, filed Feb. 13, 2020, 6 pages. [cited by applicant]